Wealthstream Advisors Inc. Grows Stake in Eli Lilly and Company (NYSE:LLY)

Wealthstream Advisors Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 4.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,332 shares of the company’s stock after purchasing an additional 54 shares during the quarter. Wealthstream Advisors Inc.’s holdings in Eli Lilly and Company were worth $1,180,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Zions Bancorporation N.A. grew its holdings in shares of Eli Lilly and Company by 12.1% during the third quarter. Zions Bancorporation N.A. now owns 9,330 shares of the company’s stock worth $8,266,000 after purchasing an additional 1,004 shares during the last quarter. Bouvel Investment Partners LLC lifted its holdings in shares of Eli Lilly and Company by 0.6% in the 3rd quarter. Bouvel Investment Partners LLC now owns 6,538 shares of the company’s stock valued at $5,792,000 after purchasing an additional 37 shares during the last quarter. Plato Investment Management Ltd boosted its position in shares of Eli Lilly and Company by 9.7% in the 3rd quarter. Plato Investment Management Ltd now owns 16,804 shares of the company’s stock valued at $14,872,000 after purchasing an additional 1,481 shares during the period. Cable Hill Partners LLC grew its stake in Eli Lilly and Company by 2.3% during the 3rd quarter. Cable Hill Partners LLC now owns 12,888 shares of the company’s stock worth $11,418,000 after buying an additional 289 shares during the last quarter. Finally, Bell Bank increased its position in Eli Lilly and Company by 1.6% during the third quarter. Bell Bank now owns 1,492 shares of the company’s stock worth $1,322,000 after buying an additional 23 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on LLY shares. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Barclays decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $811.30 on Thursday. The firm’s 50-day moving average is $888.32 and its two-hundred day moving average is $870.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a market capitalization of $770.18 billion, a P/E ratio of 87.71, a P/E/G ratio of 3.10 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. Equities analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.